$ZGNX News

Last published 4y ago

4y agoZGNXFenfluramine for Adult Dravet Patients - NCT05560282ClinicalTrials.govSeizure reduction
4y agoZGNXApproval of Fintepla, Nda #212102 (Efficacy)FDA Approved DrugsApproval Date: 03/28/2022; Drug Name: Fintepla, Nda #212102; Active Ingredients: FENFLURAMINE HYDROCHLORIDE; Company: Zogenix Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 212102
4y agoZGNXUCB Completes Acquisition of Zogenix, Inc.PR NewswireBRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ:ZGNX) for US$ 26.00 per share plus a milestone-based contingent
4y agoZGNXZogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022GlobeNewswireTwo podium and one poster presentation share important new findings on FINTEPLA's safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated
4y agoZGNXImmunicom Appoints Jennifer Haldeman as Vice President of Commercial OperationsBusiness WireExecutive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer
4y agoZGNXZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial ResultsGlobeNewswireTotal revenue of $26.6 million in the fourth quarter and $81.7 million for the full year FINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance wi
4y agoZGNXZogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial DiseasesGlobeNewswireSymptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3 Genetic testing offers a quicker, confirmatory path to diagnosis, enabling mo
4y agoDNAC VHAQ ZGNXBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq - DNAC), Viveon Health Acquisition Corp. (NYSE American - VHAQ)PR NewswireBALA CYNWYD, Pa., Jan. 26, 2022 /PRNewswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or fina
4y agoATVI DNAC VHAQ ZGNXMoore Kuehn Encourages ATVI, ZGNX, DNAC, and VHAQ Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
4y agoZGNXZGNX Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Acquisition of Zogenix by UCBGlobeNewswireMONSEY, N.Y., Jan. 19, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Zogenix, Inc. (NASDAQ:ZGNX) ("Zogenix") acted in the best interests of ZGNX shareholders in approving the proposed acquisition
4y agoADMA BEKE LPTX SOFI+1Thinking about buying stock in Zogenix, KE Holdings, SoFi Technologies, Leap Therapeutics, or ADMA Biologics?PR NewswireNEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZGNX, BEKE, SOFI, LPTX, and ADMA.
4y ago6758.T-JP ADS BAC UNH+11Stocks making the biggest moves premarket: Bank of America, UnitedHealth, P&G and moreCNBCThese are the stocks posting the largest moves before the bell.
4y agoUCBJY ZGNXUCB to acquire ZogenixPR NewswireBRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB wou
4y agoZGNXZogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet SyndromeGlobeNewswireEMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfar
4y agoZGNXZogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut SyndromeGlobeNewswireEMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Appl
4y agoZGNXZogenix Reports Granting of Inducement AwardsGlobeNewswireEMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to nine (9) new non-executive employees. The awards were made on
4y agoZGNXZogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021GlobeNewswireEMERYVILLE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will present new FINTEPLA® (fenfluramine) data from eight a
4y agoZGNXLEONIDaS Caregivers Study - NCT05140122ClinicalTrials.govAnxiety and depression scores on the Hospital Anxiety and Depression Scale (HADS), Caregiver stress scores on the UW Caregiver Stress Scale, Emotional processing biases on the Facial Expression Recognition Task (FERT)
4y agoZGNXZogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)GlobeNewswireEMERYVILLE, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority
4y agoZGNXZogenix Reports Granting of Inducement AwardsGlobeNewswireEMERYVILLE, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to thirteen (13) new non-executive employees. The awards were mad
5y agoZGNXZogenix to Participate in Two Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming i
5y agoZGNXZogenix Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsGlobeNewswireFINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectively Submitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug
5y agoZGNXZogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621GlobeNewswireEMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK
5y agoZGNXZogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4GlobeNewswireEMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30,
5y agoZGNXZogenix Reports Granting of Inducement AwardsGlobeNewswireEMERYVILLE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to thirty-four (34) new non-executive employees. The awards were
5y agoZGNXA Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder - NCT05064878ClinicalTrials.govThe median percentage change from the Baseline Period (Baseline) in "monthly (28 days) countable motor seizure frequency, The percentage of subjects who achieve a ≥ 50% reduction from Baseline in CMSF, The percentage of subjects who achieve improvement in the Clinical Global Impression-Improvement (CGI-I) rating as assessed by the Investigator, The median percentage change from Baseline in monthly ...
5y agoZGNXNew FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)GlobeNewswireMedian reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001). A Supplemental New Drug Application (sNDA) was recently submitted seeking FDA approval for the u
5y agoZGNXZogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut SyndromeGlobeNewswireSupplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company's Phase 3 trial, Study 1601, in which the primary endpoint was met with high statistical significance. Lennox-Gastaut Syndr
5y agoZGNXZogenix Reports Granting of Inducement AwardsGlobeNewswireEMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to fourteen (14) new employees. The awards were made on Septembe
5y agoZGNXZogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in JapanGlobeNewswireZogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end. Dravet syndrome is a rare, life-long form of epilepsy marked by severe seizures, significant develop
5y agoZGNXZogenix Reports Granting of Inducement AwardsGlobeNewswireEMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 20
5y agoZGNXZogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas ConferenceGlobeNewswireEMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer
5y agoZGNXZogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5GlobeNewswireEMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter end
5y agoZGNXZogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment OutcomesGlobeNewswireIn Epilepsy & Behavior editorial, authors write that FINTEPLA data demonstrate "unprecedented level of seizure control" for treated patients living with Dravet syndrome, a severe, debilitating childhood-onset epilepsy. Authors also recognize FINTEPLA f
5y agoZGNXVIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy GroupsGlobeNewswireEMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP Siblings, a new website and suite of materials create
5y agoZGNXZogenix to Participate in Two Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming
5y agoZGNXZogenix to Participate in the BofA Securities 2021 Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, a
5y agoZGNXZogenix Provides Corporate Update and Reports First Quarter 2021 Financial ResultsGlobeNewswireContinued positive momentum for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first quarter, representing quarter-over-quarter incre
5y agoZGNXZogenix, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Zogenix, Inc. (NASDAQ:ZGNX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or access a replay o
5y agoZGNXZogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral SolutionGlobeNewswireFINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. The new program supports physician access to FINTEPLA in other parts of the wor
5y agoZGNXZogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral SolutionGlobeNewswireLGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant neurodevelopmental impairment. More LGS study patients treated with FINTEPLA (fenfluramine) showed improvement i
5y agoZGNXZogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswireEMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and
5y agoZGNXZogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021GlobeNewswireSeizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure did occur.Non-Seizure benefits most commonly noted...
5y agoZGNXZogenix to Participate in the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
5y agoZGNXZogenix to Participate in the Stifel 3rd Annual CNS DayGlobeNewswireEMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
5y agoZGNXZogenix to Participate in the Raymond James Institutional Investors ConferenceGlobeNewswireEMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael...
5y agoZGNXZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial ResultsGlobeNewswirePositive momentum continues for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $8.1 million in the fourth quarter; total net sales of $9.6...
5y agoZGNXZogenix to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireEMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will...
5y agoZGNXZogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25GlobeNewswireEMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial...
5y agoZGNXZogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet SyndromeGlobeNewswireFINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental...